BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26902606)

  • 1. Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis.
    Pinheiro IM; Carvalho IP; de Carvalho CE; Brito LM; da Silva AB; Conde Júnior AM; de Carvalho FA; Carvalho AL
    Exp Parasitol; 2016 May; 164():49-55. PubMed ID: 26902606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emulgel based on amphotericin B and bacuri butter (Platonia insignis Mart.) for the treatment of cutaneous leishmaniasis: characterization and in vitro assays.
    Coêlho ES; Lopes GLN; Pinheiro IM; Holanda JNP; Alves MMM; Carvalho Nogueira N; Carvalho FAA; Carvalho ALM
    Drug Dev Ind Pharm; 2018 Oct; 44(10):1713-1723. PubMed ID: 29961344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amphotericin B-Loaded Emulgel: Effect of Chemical Enhancers on the Release Profile and Antileishmanial Activity In Vitro.
    Pinheiro IM; Carvalho IPS; Neto JAT; Lopes GLN; de Sousa Coêlho E; Sobrinho-Júnior EPC; de Moraes Alves MM; de Amorim Carvalho FA; Carvalho ALM
    AAPS PharmSciTech; 2019 Feb; 20(3):122. PubMed ID: 30805739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
    Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
    Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
    Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
    Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice.
    de Carvalho RF; Ribeiro IF; Miranda-Vilela AL; de Souza Filho J; Martins OP; Cintra e Silva Dde O; Tedesco AC; Lacava ZG; Báo SN; Sampaio RN
    Exp Parasitol; 2013 Oct; 135(2):217-22. PubMed ID: 23891944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
    Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
    Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An amphotericin B-based drug for treating experimental Leishmania major infection.
    Corware KD; Rogers M; Teo I; Müller I; Shaunak S
    Trans R Soc Trop Med Hyg; 2010 Nov; 104(11):749-50. PubMed ID: 20850850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodistribution and
    Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
    Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
    Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers.
    Solomon M; Pavlotzky F; Barzilai A; Schwartz E
    J Am Acad Dermatol; 2013 Feb; 68(2):284-9. PubMed ID: 22858005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
    Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G
    Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.
    Brown M; Noursadeghi M; Boyle J; Davidson RN
    Br J Dermatol; 2005 Jul; 153(1):203-5. PubMed ID: 16029352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
    Riezk A; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
    Molecules; 2020 Sep; 25(17):. PubMed ID: 32887341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
    Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
    Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome
    Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL
    Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.
    Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Murdan S; Croft SL
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B.
    Frankenburg S; Glick D; Klaus S; Barenholz Y
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3092-6. PubMed ID: 9835496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
    Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
    Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana.
    Varikuti S; Oghumu S; Saljoughian N; Pioso MS; Sedmak BE; Khamesipour A; Satoskar AR
    Acta Trop; 2017 Sep; 173():102-108. PubMed ID: 28602835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.